Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 26 November 2019. Jonathan Phillips.

Executive Summary

Court rulings related to the False Claims Act (FCA) this year focused on whistleblower rules and further clarifying the theory of liability given in the Supreme Court's 2016 Escobar decision. Device manufacturers, however, should also be aware of the FDA's ongoing focus on the opioid epidemic. See what Jonathan Phillips, an attorney with Gibson Dunn, said about it here.

“The whole health-care apparatus wrapping around the manufacture and sale of opioids seems to be an issue, and I think we'll see a number of enforcement efforts in the next year.” Jonathan Phillips, attorney, Gibson Dunn

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts